Analyst Price Target is $9.75
▲ +70.45% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Exscientia in the last 3 months. The average price target is $9.75, with a high forecast of $13.00 and a low forecast of $7.00. The average price target represents a 70.45% upside from the last price of $5.72.
Current Consensus is
Moderate Buy
The current consensus among 4 investment analysts is to moderate buy stock in Exscientia. This Moderate Buy consensus rating has held steady for over two years.
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Read More